Neuroprotection for ischemic stroke

Ischemic Stroke and Neuroprotection

Stroke is a major cause of morbidity and mortality in both developed and developing countries of the world. Greater understanding of the pathophysiology of neuronal damage in ischemic stroke has generated interest in neuroprotection as a management strategy. This paper aims to review the current concept and place of neuroprotection in ischemic stroke. An extensive search of all materials relate...

Oncostatin M Confers Neuroprotection against Ischemic Stroke.

UNLABELLED Cell-surface receptors provide potential targets for the translation of bench-side findings into therapeutic strategies; however, this approach for the treatment of stroke is disappointing, at least partially due to an incomplete understanding of the targeted factors. Previous studies of oncostatin M (OSM), a member of the gp130 cytokine family, have been limited, as mouse models alo...

Intranasal insulin neuroprotection in ischemic stroke

Neuroprotection in acute ischemic stroke – current status

With the growing understanding of the mechanism of cell death in ischemia, new approaches for treatment such as neuroprotection have emerged. The basic aim of this strategy is to interfere with the events of the ischemic cascade, blocking the pathological processes and preventing the death of nerve cells in the ischemic penumebra. This concept involves inhibition of the pathological molecular e...

Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke?

Erythropoietin Depletes Iron Stores: Antioxidant Neuroprotection for Ischemic Stroke? To the Editor: Sullivan1 popularized the “iron hypothesis” of ischemic heart disease in 1981, highlighting a putative role for iron as a major player in the development of atherosclerosis and subsequent cardioprotective benefits of iron depletion. This is primarily attributable to iron’s ability to catalyze Fe...